Organization · Venture Capital
Immune Boost Capital
Immune Boost Capital (IBC) is a philanthropic venture subsidiary of the Arthritis National Research Foundation, focused on investing in early-stage autoimmune diagnostics and therapeutics. It aims to bridge the funding gap for innovative therapies by recycling returns into future investments.
Overview
What Immune Boost Capital does
What Immune Boost Capital is
Immune Boost Capital (IBC) is a philanthropic venture subsidiary of the Arthritis National Research Foundation, focused on investing in early-stage autoimmune diagnostics and therapeutics. It aims to bridge the funding gap for innovative therapies by recycling returns into future investments.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2025
- Approximate age
- About 1 year
- Structured capabilities
- Funder
- Last reviewed
- May 2, 2026
Official channels
Find Immune Boost Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Immune Boost Capital as a funder
Investment thesis
Immune Boost Capital aims to bridge the funding gap between academic discovery and clinical development in autoimmune diseases by providing catalytic, early-stage funding for promising diagnostics and therapeutics.
Focus narrative
IBC focuses on investments in autoimmune and inflammatory diseases, specifically targeting diagnostics and therapeutics at or before preclinical proof-of-concept. The organization seeks to bridge the early-stage funding gap by providing initial and co-investments of up to $500,000, with potential follow-on investments to support further development. Their investment approach is milestone-driven, tied to de-risking events.
Value beyond capital
IBC provides not only funding but also strategic guidance to help portfolio companies navigate the path from early-stage development to clinical readiness. The fund's mission-first approach ensures that all returns are reinvested into future innovations in autoimmune research.
Terms and economics
- Typical check
- $100,000–$500,000
- Sweet spot
- $250,000
Focus and fit
- Stages
- Pre-seed · Seed
- Sectors
- Biotech · Healthcare · Diagnostics
- Regions
- United States
Availability
- Currently deploying
- Yes
Portfolio and track record
Portfolio context
The specific portfolio companies or notable investments are not publicly disclosed. IBC targets academic spinouts and emerging biotech companies pursuing autoimmune and inflammatory disease diagnostics, therapeutics, or enabling technologies with compelling early data.
Common questions
What to know about Immune Boost Capital
Upseed classifies Immune Boost Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 2, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.